Taiwo Adesoye1, Jessica R Schumacher1, Heather B Neuman1,2, Stephen Edge3, Daniel McKellar4, David P Winchester4, Amanda B Francescatti4, Caprice C Greenberg5,6. 1. Wisconsin Surgical Outcomes Research Program, Department of Surgery, University of Wisconsin-Madison School of Medicine and Public Health, Madison, WI, USA. 2. University of Wisconsin Carbone Cancer Center, University of Wisconsin School of Medicine and Public Health, Madison, WI, USA. 3. Roswell Park Cancer Institute, Buffalo, NY, USA. 4. American College of Surgeons, Commission On Cancer, Chicago, IL, USA. 5. Wisconsin Surgical Outcomes Research Program, Department of Surgery, University of Wisconsin-Madison School of Medicine and Public Health, Madison, WI, USA. Greenberg@surgery.wisc.edu. 6. University of Wisconsin Carbone Cancer Center, University of Wisconsin School of Medicine and Public Health, Madison, WI, USA. Greenberg@surgery.wisc.edu.
Abstract
BACKGROUND: Annual mammography is recommended after breast cancer treatment. However, studies suggest its under-utilization for Medicare patients. Utilization in the broader population is unknown, as is the role of breast magnetic resonance imaging (MRI). Understanding factors associated with imaging use is critical to improvement of adherence to recommendations. METHODS: A random sample of 9835 eligible patients receiving surgery for stages 2 and 3 breast cancer from 2006 to 2007 was selected from the National Cancer Database for primary data collection. Imaging and recurrence data were abstracted from patients 90 days after surgery to 5 years after diagnosis. Factors associated with lack of imaging were assessed using multivariable repeated measures logistic regression with generalized estimating equations. Patients were censored for death, bilateral mastectomy, new cancer, and recurrence. RESULTS: Of 9835 patients, 9622, 8702, 8021, and 7457 patients were eligible for imaging at surveillance years 1 through 4 respectively. Annual receipt of breast imaging declined from year 1 (69.5%) to year 4 (61.0%), and breast MRI rates decreased from 12.5 to 5.8%. Lack of imaging was associated with age 80 years or older and age younger than 50 years, black race, public or no insurance versus private insurance, greater comorbidity, larger node-positive hormone receptor-negative tumor, excision alone or mastectomy, and no chemotherapy (p < 0.005). Receipt of breast MRI was associated with age younger than 50 years, white race, higher education, private insurance, mastectomy, chemotherapy, care at a teaching/research facility, and MRI 12 months before diagnosis (p < 0.05). CONCLUSION: Under-utilization of mammography after breast cancer treatment is associated with sociodemographic and clinical factors, not institutional characteristics. Effective interventions are needed to increase surveillance mammography for at-risk populations. ClinicalTrials.gov Identifier: NCT02171078.
BACKGROUND: Annual mammography is recommended after breast cancer treatment. However, studies suggest its under-utilization for Medicare patients. Utilization in the broader population is unknown, as is the role of breast magnetic resonance imaging (MRI). Understanding factors associated with imaging use is critical to improvement of adherence to recommendations. METHODS: A random sample of 9835 eligible patients receiving surgery for stages 2 and 3 breast cancer from 2006 to 2007 was selected from the National Cancer Database for primary data collection. Imaging and recurrence data were abstracted from patients 90 days after surgery to 5 years after diagnosis. Factors associated with lack of imaging were assessed using multivariable repeated measures logistic regression with generalized estimating equations. Patients were censored for death, bilateral mastectomy, new cancer, and recurrence. RESULTS: Of 9835 patients, 9622, 8702, 8021, and 7457 patients were eligible for imaging at surveillance years 1 through 4 respectively. Annual receipt of breast imaging declined from year 1 (69.5%) to year 4 (61.0%), and breast MRI rates decreased from 12.5 to 5.8%. Lack of imaging was associated with age 80 years or older and age younger than 50 years, black race, public or no insurance versus private insurance, greater comorbidity, larger node-positive hormone receptor-negative tumor, excision alone or mastectomy, and no chemotherapy (p < 0.005). Receipt of breast MRI was associated with age younger than 50 years, white race, higher education, private insurance, mastectomy, chemotherapy, care at a teaching/research facility, and MRI 12 months before diagnosis (p < 0.05). CONCLUSION: Under-utilization of mammography after breast cancer treatment is associated with sociodemographic and clinical factors, not institutional characteristics. Effective interventions are needed to increase surveillance mammography for at-risk populations. ClinicalTrials.gov Identifier: NCT02171078.
Authors: Abhishek D Parmar; Kristin M Sheffield; Gabriela M Vargas; Yimei Han; Celia Chao; Taylor S Riall Journal: Surgery Date: 2013-08 Impact factor: 3.982
Authors: Meredith M Regan; Patrick Neven; Anita Giobbie-Hurder; Aron Goldhirsch; Bent Ejlertsen; Louis Mauriac; John F Forbes; Ian Smith; István Láng; Andrew Wardley; Manuela Rabaglio; Karen N Price; Richard D Gelber; Alan S Coates; Beat Thürlimann Journal: Lancet Oncol Date: 2011-10-20 Impact factor: 41.316
Authors: Marco Colleoni; Zhuoxin Sun; Karen N Price; Per Karlsson; John F Forbes; Beat Thürlimann; Lorenzo Gianni; Monica Castiglione; Richard D Gelber; Alan S Coates; Aron Goldhirsch Journal: J Clin Oncol Date: 2016-01-19 Impact factor: 44.544
Authors: Diana S M Buist; Linn A Abraham; William E Barlow; Arun Krishnaraj; Regan C Holdridge; Edward A Sickles; Patricia A Carney; Karla Kerlikowske; Berta M Geller Journal: Breast Cancer Res Treat Date: 2010-08-11 Impact factor: 4.872
Authors: Ann Eka-Ete P Etim; Kenneth G Schellhase; Rodney Sparapani; Ann B Nattinger Journal: Breast Cancer Res Treat Date: 2006-03-15 Impact factor: 4.872
Authors: Terry S Field; Chyke Doubeni; Matthew P Fox; Diana S M Buist; Feifei Wei; Ann M Geiger; Virginia P Quinn; Timothy L Lash; Marianne N Prout; Marianne Ulcickas Yood; Floyd J Frost; Rebecca A Silliman Journal: J Gen Intern Med Date: 2007-12-01 Impact factor: 5.128
Authors: Carey K Anders; David S Hsu; Gloria Broadwater; Chaitanya R Acharya; John A Foekens; Yi Zhang; Yixin Wang; P Kelly Marcom; Jeffrey R Marks; Phillip G Febbo; Joseph R Nevins; Anil Potti; Kimberly L Blackwell Journal: J Clin Oncol Date: 2008-07-10 Impact factor: 44.544
Authors: Claire F Snyder; Kevin D Frick; Kimberly S Peairs; Melinda E Kantsiper; Robert J Herbert; Amanda L Blackford; Antonio C Wolff; Craig C Earle Journal: J Gen Intern Med Date: 2009-01-21 Impact factor: 5.128
Authors: E La Rocca; M Silvestri; G Pruneri; S Di Cosimo; M C De Santis; E Ortolan; M Valenti; S Folli; F G de Braud; G V Bianchi; G P Scaperrotta; G Apolone; M G Daidone; V Cappelletti Journal: J Cancer Res Clin Oncol Date: 2022-04-09 Impact factor: 4.322